Alternative Data for Corcept Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 39 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 24,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 63 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,433 | Sign up | Sign up | Sign up |
| X Mentions | 10 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 64 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 51 | Sign up | Sign up | Sign up |
| Linkedin Employees | 708 | Sign up | Sign up | Sign up |
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
| Price | $36.27 |
| Target Price | Sign up |
| Volume | 632,000 |
| Market Cap | $3.94B |
| Year Range | $34.8 - $90.32 |
| Dividend Yield | 0% |
| PE Ratio | 42.94 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens BermanJanuary 9 - GlobeNewswire |
|
 |
Price Targets Lowered on Corcept Therapeutics (CORT) After FDA LetterJanuary 8 - Yahoo |
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Incorporated on Behalf of Corcept Stockholders and Encourages Investors to Contact the FirmJanuary 8 - GlobeNewswire |
|
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)January 8 - GlobeNewswire |
|
|
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?January 8 - Yahoo |
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORTJanuary 6 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 208M | 4.6M | 203M | 19M | 16M | 0.160 |
| Q2 '25 | 194M | 3.4M | 191M | 35M | 27M | 0.290 |
| Q1 '25 | 157M | 2.4M | 155M | 20M | 3.9M | 0.169 |
| Q4 '24 | 182M | 3M | 179M | 30M | 26M | 0.260 |
| Q3 '24 | 183M | 2.9M | 180M | 47M | 47M | 0.410 |
Insider Transactions View All
| Guyer William filed to sell 1,235 shares at $35.2. January 8 '26 |
| Guyer William filed to sell 1,235 shares at $80.9. December 3 '25 |
| Guyer William filed to sell 1,875 shares at $80. December 3 '25 |
| Lyon Joseph Douglas filed to sell 10,277 shares at $79.5. December 3 '25 |
| BELANOFF JOSEPH K filed to sell 2,701,370 shares at $79.8. December 3 '25 |
Similar companies
Read more about Corcept Therapeutics (CORT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Corcept Therapeutics?
The Market Cap of Corcept Therapeutics is $3.94B.
What is Corcept Therapeutics' PE Ratio?
As of today, Corcept Therapeutics' PE (Price to Earnings) ratio is 42.94.
What is the current stock price of Corcept Therapeutics?
Currently, the price of one share of Corcept Therapeutics stock is $36.27.
How can I analyze the CORT stock price chart for investment decisions?
The CORT stock price chart above provides a comprehensive visual representation of Corcept Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Corcept Therapeutics shares. Our platform offers an up-to-date CORT stock price chart, along with technical data analysis and alternative data insights.
Does CORT offer dividends to its shareholders?
As of our latest update, Corcept Therapeutics (CORT) does not offer dividends to its shareholders. Investors interested in Corcept Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Corcept Therapeutics?
Some of the similar stocks of Corcept Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
